Cargando…

Machine Learning for Prediction of Survival Outcomes with Immune-Checkpoint Inhibitors in Urothelial Cancer

SIMPLE SUMMARY: Machine learning (ML) is a form of artificial intelligence that could be used to enhance the efficiency of developing accurate prediction models for survival outcomes with cancer medicines, which is critical in informing disease prognosis and care planning. We used data from two rece...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abuhelwa, Ahmad Y., Kichenadasse, Ganessan, McKinnon, Ross A., Rowland, Andrew, Hopkins, Ashley M., Sorich, Michael J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122430/ https://www.ncbi.nlm.nih.gov/pubmed/33919237 http://dx.doi.org/10.3390/cancers13092001

Ejemplares similares

Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial
por: Hopkins, Ashley M., et al.
Publicado: (2021)

Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176”
por: Hopkins, Ashley M., et al.
Publicado: (2021)

Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers
por: Hopkins, Ashley M, et al.
Publicado: (2017)

C-reactive protein provides superior prognostic accuracy than the IMDC risk model in renal cell carcinoma treated with Atezolizumab/Bevacizumab
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2022)

The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data
por: Modi, Natansh D., et al.
Publicado: (2021)

Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab
por: Hopkins, Ashley M, et al.
Publicado: (2020)

Nuances to precision dosing strategies of targeted cancer medicines
por: Hopkins, Ashley M., et al.
Publicado: (2020)

The Influence of Pre-Existing Beta-Blockers Use on Survival Outcomes in HER2 Positive Advanced Breast Cancer: Pooled Analysis of Clinical Trial Data
por: Modi, Natansh D., et al.
Publicado: (2020)

Heterogeneity and Utility of Pharmaceutical Company Sharing of Individual-Participant Data Packages
por: Hopkins, Ashley M., et al.
Publicado: (2023)

The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy
por: Badaoui, Sarah, et al.
Publicado: (2022)

Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'
por: Rowland, Andrew, et al.
Publicado: (2015)

Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials
por: Hopkins, Ashley M., et al.
Publicado: (2020)

Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
por: Booth, Andrew E. C., et al.
Publicado: (2020)

Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel
por: Hopkins, Ashley M., et al.
Publicado: (2019)

A clinical scoring tool validated with machine learning for predicting severe hand–foot syndrome from sorafenib in hepatocellular carcinoma
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2022)

Artificial intelligence chatbots will revolutionize how cancer patients access information: ChatGPT represents a paradigm-shift
por: Hopkins, Ashley M, et al.
Publicado: (2023)

Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data
por: Sorich, Michael J, et al.
Publicado: (2016)

Predictors of anti-VEGF drug-induced hypertension using different hypertension criteria: a secondary analysis of the COMPARZ study
por: Mangoni, Arduino A., et al.
Publicado: (2018)

Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib
por: Modi, Natansh D., et al.
Publicado: (2021)

Commentary: Association Between Antihypertensive Medication Use and Breast Cancer: A Systematic Review and Meta-Analysis
por: Modi, Natansh D., et al.
Publicado: (2021)

Early Adverse Events predict Survival Outcomes in HER2-positive Advanced Breast Cancer Patients treated with Lapatinib plus Capecitabine
por: Ang, Fang L.I., et al.
Publicado: (2020)

Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration
por: Modi, Natansh D., et al.
Publicado: (2022)

A 10-year update to the principles for clinical trial data sharing by pharmaceutical companies: perspectives based on a decade of literature and policies
por: Modi, Natansh D., et al.
Publicado: (2023)

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
por: Rowland, A, et al.
Publicado: (2015)

Immune checkpoint inhibitors for urothelial carcinoma
por: Kim, Hyung Suk, et al.
Publicado: (2018)

Targeted pharmacotherapy after somatic cancer mutation screening
por: Polasek, Thomas M., et al.
Publicado: (2016)

Immune Checkpoint Inhibitors and Long-term Survival of Patients With Metastatic Urothelial Cancer
por: Zhu, Alec, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma
por: Patel, Aakash, et al.
Publicado: (2021)

The Evolution of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
por: Houssiau, Hélène, et al.
Publicado: (2022)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020)

Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer
por: Parent, Pauline, et al.
Publicado: (2023)

A critical analysis of barriers to the clinical implementation of pharmacogenomics
por: McKinnon, Ross A, et al.
Publicado: (2007)

Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancer
por: Modi, N.D., et al.
Publicado: (2022)

Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook
por: Gopalakrishnan, Dharmesh, et al.
Publicado: (2018)

Immune checkpoint inhibitors as a real hope in advanced urothelial carcinoma
por: Seront, Emmanuel, et al.
Publicado: (2018)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
por: Wang, Di, et al.
Publicado: (2021)

Cost-Effectiveness of Immune Checkpoint Inhibitors in Urothelial Carcinoma—A Review
por: Walia, Arman S., et al.
Publicado: (2021)

Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2020)

Survival Outcomes of Nonsmall Cell Lung Cancer Patients Treated with Afatinib Who Are Affected by Early Adverse Events
por: Logan, Jessica M., et al.
Publicado: (2021)

Data sharing from pharmaceutical industry sponsored clinical studies: audit of data availability
por: Hopkins, Ashley M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7jei5hv7ag0200s4areup5v23h